Login to Your Account



Twice-Failed, and Yet . . .

Untangling Prochymal's Bid: Data Hint at Osiris Triumph

By Randy Osborne


Monday, June 29, 2009
Mixed interim Phase II data with Prochymal chronic obstructive pulmonary disease - good safety, not-so-great efficacy - laid a ball of confusion on Wall Street's doorstep that prompted sharply differing opinions about the future of the adult mesenchymal stem cell candidate from Osiris Therapeutics Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription